Doseology Sciences (MOOD) AI Stock Analysis

• Market Cap: C$6.41M
• Dividend Yield: N/A
• Average Volume (3M): 1.79K
• Price to Earnings (P/E): ―
• Beta (1Y): -3.51
• Revenue Growth: -50.89%
• EPS Growth: -32.33%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 8,011,621
• 10 Day Avg. Volume: 3,383
• 30 Day Avg. Volume: 1,793
• PEG Ratio: -0.49
• Price to Book (P/B): 3.46
• Price to Sales (P/S): 113.73
• P/FCF Ratio: -14.14
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: C$0.79 ▲(48.68% Upside)

The score is mainly constrained by weak financial performance—small/volatile revenue, continued losses, and negative operating/free cash flow—despite a clean, low-debt balance sheet. Technicals are moderately supportive with price above major moving averages but neutral momentum, while valuation is hindered by negative earnings and no dividend yield data.

Positive Factors

Low leverage / clean balance sheet

Effectively zero debt is a durable structural advantage: it reduces solvency and refinancing risk during revenue volatility, preserves strategic optionality for M&A or capex, and lowers fixed financial costs. This gives management time to scale the business without immediate debt pressure.

Niche dosage-controlled cannabis wellness products

A focused product strategy in dosage-controlled cannabinoid wellness targets a growing, regulatory-aware consumer segment and supports brand differentiation. Durable product specialization can drive repeat purchases, higher margins, and clearer route-to-market versus commoditized commodity producers.

Improving cash burn trajectory

Material improvement in cash burn signals management is exercising cost discipline and moving toward a more sustainable cash profile. If maintained, this reduces future financing needs and lengthens runway, improving odds of achieving break-even or funding growth from smaller raises.

Negative Factors

Small, volatile and declining revenue

Declining and highly variable revenue undermines ability to scale fixed costs, achieve operating leverage, and build durable margins. Persistent top-line weakness over multiple periods raises execution risk for commercialization and limits visibility into sustainable cash generation.

Consistently negative operating and free cash flow

Ongoing negative operating and free cash flow forces reliance on external financing, which can dilute shareholders and constrain long-term planning. Continued cash deficits limit capacity to invest in marketing, R&D, or inventory needed to scale the consumer business.

Persistent operating losses and negative ROE

Sustained operating losses and negative ROE indicate the business has not reached profitable scale and are eroding the equity base over time. This structural profitability gap increases the risk that additional capital will be needed to sustain operations or retool the business model.

Doseology Sciences Business Overview & Revenue Model

Company Description

Doseology Sciences Inc. engages in the cultivation and extraction of nutraceutical and pharmaceutical products in Canada. It focuses on research, development, and sale of medicinal mushroom products, including tinctures and powders. The company sells its products online through doseology.com. Doseology Sciences Inc. was incorporated in 2019 and is based in Kelowna, Canada.

How the Company Makes Money

Doseology Sciences, Inc. generates revenue through the sale of its health and wellness products. The company's primary revenue streams come from direct-to-consumer sales via their online platform and distribution through retail partnerships. These partnerships may include health food stores, pharmacies, and other retailers that carry wellness products. Additionally, the company may engage in licensing agreements or partnerships that allow them to expand their product reach and customer base. Marketing and strategic collaborations help to bolster their market presence and drive sales growth.

Doseology Sciences Financial Statement Overview

Summary

Overall financials reflect an early-stage, loss-making profile: very small/volatile revenue with sizable ongoing losses (Income Statement score 18) and consistently negative operating/free cash flow despite some burn improvement (Cash Flow score 24). The main offset is a relatively strong balance sheet with effectively no debt (Balance Sheet score 62).

Income Statement

Revenue remains very small and volatile (down ~27% in 2025 vs. 2024), and profitability is weak with large ongoing losses (2025 net margin roughly -10.5%). While gross profit is positive in recent years, operating losses remain sizable relative to revenue, indicating the business has not yet scaled to cover operating costs.

Balance Sheet

The balance sheet is a relative strength: debt is effectively zero in the latest two years, and equity exceeds total assets by a wide margin (suggesting limited leverage risk). However, persistent losses are eroding returns for shareholders (negative return on equity across all periods), which can pressure the equity base over time if losses continue.

Cash Flow

Cash generation is weak with consistently negative operating cash flow and negative free cash flow each year (2025 operating cash flow about -$342K). Cash burn improved materially versus prior years (notably compared with 2022–2023), but cash flow still does not support self-funding operations and leaves the company dependent on external capital if spending persists.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	20.29K	42.56K	98.52K	43.09K	16.05K	0.00
Gross Profit	9.98K	18.89K	72.09K	41.29K	-148.38K	-92.83K
EBITDA	-389.53K	-471.61K	-319.48K	-1.78M	-1.72M	-1.47M
Net Income	-370.38K	-447.79K	-339.85K	-1.78M	-1.94M	-1.63M
Balance Sheet
Total Assets	1.49M	1.49M	1.10M	1.40M	3.87M	5.99M
Cash, Cash Equivalents and Short-Term Investments	1.43M	1.43M	1.06M	1.30M	1.87M	3.73M
Total Debt	0.00	0.00	0.00	50.27K	746.10K	687.54K
Total Liabilities	94.11K	94.11K	82.49K	99.19K	871.51K	3.41M
Stockholders Equity	1.40M	1.40M	1.02M	1.30M	3.00M	2.58M
Cash Flow
Free Cash Flow	-230.84K	-342.24K	-235.12K	-481.05K	-1.72M	-2.54M
Operating Cash Flow	-230.85K	-342.24K	-235.12K	-481.05K	-1.71M	-2.37M
Investing Cash Flow	0.00	0.00	0.00	0.00	-7.88K	-26.05K
Financing Cash Flow	711.68K	711.68K	-6.14K	-91.88K	-140.08K	5.79M

Doseology Sciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.53
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MOOD, the sentiment is Positive. The current price of 0.53 is below the 20-day moving average (MA) of 0.70, below the 50-day MA of 0.69, and below the 200-day MA of 0.62, indicating a bullish trend. The MACD of 0.01 indicates Positive momentum. The RSI at 55.47 is Neutral, neither overbought nor oversold. The STOCH value of 20.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:MOOD.

Doseology Sciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MOOD	47 Neutral	C$6.41M	-7.94	-41.36%	―	-50.89%	-32.33%
ENBI	47 Neutral	C$1.39M	-3.36	-107.76%	―	―	34.22%
DOSE	43 Neutral	C$19.12M	-4.34	―	―	95.76%	22.56%

Doseology Sciences Corporate Events

Doseology Launches Pilot for Caffeine Energy Pouches Under Feed That Brain Brand

Doseology Sciences has begun a pilot production run of non-nicotine, caffeine-based energy pouches under its Feed That Brain brand, positioning the platform at the center of its broader oral stimulant strategy. The initiative is designed as a controlled, data-driven test of pouch-based caffeine delivery, emphasizing measured, predictable energy and user control rather than intensity, and will use limited direct-to-consumer distribution to gather product, consumer, and operational insights that could shape future formulations, delivery formats, and commercialization in the rapidly expanding, yet increasingly scrutinized, global energy-products market.

The most recent analyst rating on (TSE:MOOD) stock is a Hold with a C$0.77 price target. To see the full list of analyst forecasts on Doseology Sciences stock, see the TSE:MOOD Stock Forecast page.

Doseology Boosts Transparency With New Annual Information Form Filing

Doseology Sciences Inc. has filed its Annual Information Form for the fiscal year ended June 30, 2025 on SEDAR+, consolidating its business, strategy, risk factors, governance practices, and capital structure into a single, structured disclosure document. The move is positioned as a governance and transparency measure aimed at improving investors’ access to information and preserving future capital markets flexibility, including potential short-form prospectus eligibility, while the company stresses that no financing or public offering is being announced at this time and that the filing reflects its evolved operating profile following platform development and its first acquisition.

The most recent analyst rating on (TSE:MOOD) stock is a Hold with a C$0.78 price target. To see the full list of analyst forecasts on Doseology Sciences stock, see the TSE:MOOD Stock Forecast page.

Doseology Taps McKinney Advisors to Fast-Track Regulatory Path for Oral Pouch Line

Doseology Sciences has entered a strategic partnership with McKinney Regulatory Science Advisors to accelerate the regulatory and commercial development of its innovative oral pouch products. The engagement is designed to fast-track the company’s navigation of FDA pathways, particularly for nicotine and nicotine-analogue formulations, by integrating regulatory strategy into formulation, testing, manufacturing validation, and post-market compliance. By leveraging McKinney’s expertise in PMTA preparation, labelling, claims, and surveillance, Doseology aims to strengthen its intellectual property, ensure dose consistency and consumer safety, and position itself as a science-led frontrunner in the emerging market for regulated oral stimulant pouches.

The most recent analyst rating on (TSE:MOOD) stock is a Hold with a C$0.70 price target. To see the full list of analyst forecasts on Doseology Sciences stock, see the TSE:MOOD Stock Forecast page.

Doseology Launches Investor Communications Initiative to Boost Market Engagement

Doseology Sciences Inc. has launched an Investor Communications Initiative to enhance its disclosure practices and investor engagement, supporting its long-term commercial and capital-markets strategy. This initiative includes partnerships with Guerilla Capital and Maynard Communications Ltd. to improve corporate updates distribution, visibility, and media exposure. The program aims to align Doseology’s operations with enhanced reporting standards and capitalize on the growing demand for oral stimulant products, positioning the company advantageously within the evolving market.

Doseology Secures Strategic Manufacturing Agreement for Market Readiness

Doseology Sciences Inc. has announced a significant milestone with its subsidiary, Doseology USA Inc., securing a strategic manufacturing agreement with a leading North American partner. This agreement marks a crucial step in Doseology’s transition from research and development to commercial deployment of its oral stimulant pouches. The partnership ensures the company has the necessary manufacturing capacity, regulatory compliance, and operational infrastructure to enter the market effectively. This development is expected to enhance Doseology’s market positioning and shareholder value by establishing a solid foundation for scalable and responsible commercialization.